title: Helicobacter pylori-positive duodenal ulcer: a long-term double-blind randomized study in patients healed with H2-receptor antagonists.
abstract: BACKGROUND
  The NIH Consensus Conference in 1994 (1) concluded that all patients with peptic ulcer disease should be tested and treated for Helicobacter pylori and that further evaluation was needed for patients in remission.
  
  
  METHODS
  We evaluated in a double blind randomization 30 patients whose duodenal ulcers had been healed with H2-receptor antagonists and who remained in remission on maintenance therapy. After ulcer healing and the presence of H. pylori had been confirmed, these patients were randomized to receive eradication therapy or placebo and were followed for a mean period of 23 months.
  
  
  RESULTS
  Almost all patients receiving placebo had ulcer recurrence, whereas the patients treated with antibiotics demonstrate a low recurrence rate.
  
  
  CONCLUSIONS
  These data suggest, for the first time to our knowledge, the importance of treating with antibiotics duodenal ulcer patients whose disease is in remission.
authors.affiliation: Servizio di Endoscopia e di Microbiologia Ospedale di Rivoli, Torino, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Suriani
authors.forename: M
authors.initials: M
authors.lastname: Ravizza
authors.forename: C
authors.initials: C
authors.lastname: Pallante
authors.forename: D
authors.initials: D
authors.lastname: Mazzucco
authors.forename: E
authors.initials: E
authors.lastname: Cardesi
authors.forename: M
authors.initials: M
authors.lastname: Colozza
authors.forename: M
authors.initials: M
authors.lastname: Malandrino
authors.forename: R
authors.initials: R
authors.lastname: Oneglio
authors.forename: G
authors.initials: G
authors.lastname: Orso Giacone
authors.forename: P
authors.initials: P
authors.lastname: Dusio
authors.forename: M
authors.initials: M
authors.lastname: Vajo
mesh_terms: D000328:Adult; D000368:Aged; D000863:Antacids / Q000008:administration & dosage / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004311:Double-Blind Method; D004318:Doxycycline / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology / Q000517:prevention & control; D005260:Female; D005756:Gastritis / Q000150:complications* / Q000188:drug therapy; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D015993:Life Tables; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D011899:Ranitidine / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction
chemical_list: D000863:Antacids; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D009942:Organometallic Compounds; D008795:Metronidazole; D011899:Ranitidine; C002791:bismuth tripotassium dicitrate; D004318:Doxycycline